3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Dermatologic
1
Conditions
Melanoma
5
Neoplasms
3
Glioma
3
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
2
Gliosarcoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Head and Neck Neoplasms
1
Ependymoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Doxorubicin
62
Ifosfamide
39
Gemcitabine
29
Radiotherapy
27
Filgrastim
27
Cyclophosphamide
26
Docetaxel
19
Vincristine
18
pembrolizumab
17
Etoposide
17
pazopanib
16
Cisplatin
16
Nivolumab
15
Trabectedin
14
apatinib
13
Magnetic Resonance Spectroscopy
13
Carboplatin
12
Irinotecan
11
Bevacizumab
11
Temozolomide
10
Sirolimus
10
camrelizumab
9
anlotinib
9
Surgical Procedures, Operative
9
Sorafenib
9
Paclitaxel
9
Ipilimumab
9
Injections
9
Dactinomycin
9
Topotecan
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma
×
poly ICLC
×
Clear all
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled